Cargando…
Targeted anti-vascular therapies for ovarian cancer: current evidence
Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%. Over 80% of patients with advanced ovarian cancer will relap...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566823/ https://www.ncbi.nlm.nih.gov/pubmed/23385789 http://dx.doi.org/10.1038/bjc.2012.541 |
_version_ | 1782258608914825216 |
---|---|
author | Hall, M Gourley, C McNeish, I Ledermann, J Gore, M Jayson, G Perren, T Rustin, G Kaye, S |
author_facet | Hall, M Gourley, C McNeish, I Ledermann, J Gore, M Jayson, G Perren, T Rustin, G Kaye, S |
author_sort | Hall, M |
collection | PubMed |
description | Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%. Over 80% of patients with advanced ovarian cancer will relapse and despite a good chance of remission from further chemotherapy, they will usually die from their disease. Sequential treatment strategies are employed to maximise quality and length of life but patients eventually become resistant to cytotoxic agents. The expansion in understanding of the molecular biology that characterises cancer cells has led to the rapid development of new agents to target important pathways but the heterogeneity of ovarian cancer biology means that there is no predominant defect. This review attempts to discuss progress to date in tackling a more general target applicable to ovary cancer—angiogenesis. |
format | Online Article Text |
id | pubmed-3566823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-35668232013-02-08 Targeted anti-vascular therapies for ovarian cancer: current evidence Hall, M Gourley, C McNeish, I Ledermann, J Gore, M Jayson, G Perren, T Rustin, G Kaye, S Br J Cancer Minireview Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%. Over 80% of patients with advanced ovarian cancer will relapse and despite a good chance of remission from further chemotherapy, they will usually die from their disease. Sequential treatment strategies are employed to maximise quality and length of life but patients eventually become resistant to cytotoxic agents. The expansion in understanding of the molecular biology that characterises cancer cells has led to the rapid development of new agents to target important pathways but the heterogeneity of ovarian cancer biology means that there is no predominant defect. This review attempts to discuss progress to date in tackling a more general target applicable to ovary cancer—angiogenesis. Nature Publishing Group 2013-02-05 2013-02-05 /pmc/articles/PMC3566823/ /pubmed/23385789 http://dx.doi.org/10.1038/bjc.2012.541 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Minireview Hall, M Gourley, C McNeish, I Ledermann, J Gore, M Jayson, G Perren, T Rustin, G Kaye, S Targeted anti-vascular therapies for ovarian cancer: current evidence |
title | Targeted anti-vascular therapies for ovarian cancer: current evidence |
title_full | Targeted anti-vascular therapies for ovarian cancer: current evidence |
title_fullStr | Targeted anti-vascular therapies for ovarian cancer: current evidence |
title_full_unstemmed | Targeted anti-vascular therapies for ovarian cancer: current evidence |
title_short | Targeted anti-vascular therapies for ovarian cancer: current evidence |
title_sort | targeted anti-vascular therapies for ovarian cancer: current evidence |
topic | Minireview |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566823/ https://www.ncbi.nlm.nih.gov/pubmed/23385789 http://dx.doi.org/10.1038/bjc.2012.541 |
work_keys_str_mv | AT hallm targetedantivasculartherapiesforovariancancercurrentevidence AT gourleyc targetedantivasculartherapiesforovariancancercurrentevidence AT mcneishi targetedantivasculartherapiesforovariancancercurrentevidence AT ledermannj targetedantivasculartherapiesforovariancancercurrentevidence AT gorem targetedantivasculartherapiesforovariancancercurrentevidence AT jaysong targetedantivasculartherapiesforovariancancercurrentevidence AT perrent targetedantivasculartherapiesforovariancancercurrentevidence AT rusting targetedantivasculartherapiesforovariancancercurrentevidence AT kayes targetedantivasculartherapiesforovariancancercurrentevidence |